Clinical trials: Metastatic Renal Cell Carcinoma (mRCC)
Kidney Neoplasms
Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries
The objectives of this study is to investigate treatment patterns and outcomes for Sutent and Inlyta in mRCC patients in a nationwide population-based setting in Sweden.
- Trial name
- NCT04669366
- Testing
- sunitinib, axitinib
- Where
- Sweden
- Volunteers
- 1,205 people
- Sponsor
- Pfizer
Metastatic Renal Cell Carcinoma
Sequential Therapy in Metastatic Renal Cell Carinoma
Sequential therapy with BEvacizumab, RAd001 (everolimus) and Tyrosinekinase inhibitors (TKI) in metastatic renal cell carcinoma (mRCC)
- Trial name
- BERAT (NCT01731158)
- Testing
- Avastin in combination with Roferon-A, Afinitor, TKI: Sutent, Nexavar or Votrient
- Where
- 13 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Central European Society for Anticancer Drug Research
Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent /…
- Conditions
- Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
- Trial name
- STAR-TOR (NCT00700258)
- Testing
- Temsirolimus, Sunitinib, Axitinib
- Where
- 77 sites in Germany
- Volunteers
- 1,520 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
Sorafenib in Elderly mRCC
This prospective, single arm, multi-center pilot study includes 120 mRCC patients over 65 years, no prior systemic treatment, determined to be candidates for systemic therapy by the investigator.
- Trial name
- NCT01728948
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Bayer
Stage IV Renal Cell Cancer AJCC V7
A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients
This study is designed as a phase-II proof of concept trial to investigate if a treatment strategy where stereotactic body radiation therapy (SBRT) is given with pembrolizumab is sufficiently active to warrant further…
- Trial name
- OZM-065 (NCT02599779)
- Testing
- Pembrolizumab, Stereotactic Body Radiation Therapy
- Where
- 3 sites in Canada
- Volunteers
- 4 people
- Sponsor
- Sunnybrook Health Sciences Centre
Metastatic Renal Cell Carcinoma
Second Line Sorafenib After Pazopanib in Patients With RCC
Retrospective studies showed Sorafenib's efficacy as second line treatment after a Tyrosine Kinase Inhibitor (TKI). Currently there is no standard of treatment in 2nd line for patients treated in first line with pazopanib for…
- Trial name
- SOAP (NCT02122003)
- Testing
- Sorafenib
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Renal Cell Carcinoma
Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)
This study is a multicenter, non-interventional, retrospective, medical chart review of patients with metastatic renal cell cancer(mRCC) treated with avelumab plus axitinib as a first-line therapy in Japan between 20 December…
- Trial name
- NCT05012865
- Testing
- avelumab, axitinib
- Where
- 12 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Pfizer
Renal Cell Carcinoma (RCC)
First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain
This retrospective observational study will use anonymized electronic medical records from the BIG-PAC® database to describe outcomes and treatment management for adults in Spain with advanced or metastatic renal cell carcinoma…
- Trial name
- INSPIRE-RCC (NCT07852884)
- Testing
- First-line systemic regimens
- Where
- Spain
- Volunteers
- 1,200 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Renal Cell Carcinoma (mRCC)
Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting
This is an international, multi-centre, prospective (partly retrospective), observational study to evaluate treatment patterns and clinical outcomes in patients with advanced or metastatic RCC treated with sunitinib in first line…
- Trial name
- ADONIS (NCT02184416)
- Testing
- observational
- Where
- 110 sites in Austria, Belgium and 6 more
- Volunteers
- 554 people
- Sponsor
- Pfizer
Breast Cancer, Colorectal Cancer
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
This pilot, non-interventional, observational, Web-based, prospective cohort study is designed to collect self-reported safety and effectiveness and genetic data from subjects with locally recurrent breast cancer (BC) or…
- Conditions
- Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma
- Trial name
- NCT01598597
- Where
- 50 sites in United States
- Volunteers
- 276 people
- Sponsor
- Genentech, Inc.
Advanced or Metastatic Renal Cell Carcinoma, Renal Cancer
Study In Patients With Kidney Cancer Treated With Sutent
Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.
- Trial name
- NCT00873210
- Testing
- Sutent
- Where
- 14 sites in Slovakia
- Volunteers
- 121 people
- Sponsor
- Pfizer
Metastatic Solid Tumor, Advanced Solid Tumor
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
- Trial name
- NCT05479812
- Testing
- WTX-124, pembrolizumab
- Where
- 14 sites in United States
- Volunteers
- 156 people
- Sponsor
- Werewolf Therapeutics, Inc.
Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread…
- Conditions
- Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm
- Trial name
- NCT07227415
- Testing
- PF-08634404, Ipilimumab, Axitinib
- Where
- 183 sites in United States, Australia and 4 more
- Volunteers
- 224 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
Tumor Registry of Advanced Renal Cell Carcinoma
The purpose of this registry is to record information of therapy reality of metastatic or locally advanced Renal Cell Carcinoma by office-based medical oncologists in Germany.
- Trial name
- RCC-Registry (NCT00610012)
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- iOMEDICO AG
Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.
The purpose of this study is to understand how patients with mRCC respond to the study medicine (called sunitinib) when they receive it as the first line of treatment after finding out the cause for the disease.
- Trial name
- NCT05745142
- Testing
- Sunitinib
- Where
- Turkey (Türkiye)
- Volunteers
- 376 people
- Sponsor
- Pfizer
Metastatic Renal Cell Carcinoma
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
To evaluate the combination of PF-04856884 (CVX-060) in combination with Axitinib (AG-013736) in patients that have received one prior systemic regimen for metastatic renal cell carcinoma (mRCC) vs. axitinib alone.
- Trial name
- NCT01441414
- Testing
- PF-04856884, Axitinib (AG-013736)
- Where
- 29 sites in United States, Czechia
- Volunteers
- 18 people
- Sponsor
- Pfizer
Metastatic Clear Cell Renal Cell Carcinoma
Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
Nivolumab (brand name Opdivo): IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist, until disease progression or unacceptable toxicity; SABR, dose…
- Trial name
- NCT02781506
- Testing
- Nivolumab, SAbR
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Renal Cell Carcinoma
Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)
This study is a multicenter, non-interventional, retrospective, medical chart review of participants with metastatic renal cell cancer(mRCC) treated with avelumab plus axitinib as a first-line therapy in Japan between 20 December…
- Trial name
- NCT05650164
- Testing
- avelumab, axitinib
- Where
- 19 sites in Japan
- Volunteers
- 171 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Metastatic Renal Cell Carcinoma
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
Primary objective: to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of SUTENT®.
- Trial name
- NCT00684645
- Testing
- SUTENT
- Where
- 20 sites in Czechia
- Volunteers
- 186 people
- Sponsor
- Pfizer
Metastatic Renal Cell Carcinoma
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
The purpose of this study is to learn about the effectiveness of the first and later lines of medicines on clinical outcomes in people with mRCC.
- Trial name
- NCT05858749
- Where
- United States
- Volunteers
- 494 people
- Sponsor
- Pfizer